Business Wire

NY-MOODY'S-ANALYTICS

10.6.2019 08:32:06 CEST | Business Wire | Press release

Share
Moody’s Analytics to Provide Certification for Hungarian Mortgage Professionals

Moody's Analytics has announced the launch of the Certification of Professional Competence in Mortgage Lending in Hungary, in collaboration with the Budapest Institute of Banking (BIB) and the International Training Center for Bankers (ITCB).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005060/en/

The certification program meets the requirements of the European Parliament and Council Directive on Mortgage Credit. The objective of the mandate is to ensure a minimum standard of competency and ethics among mortgage lenders, specifically applicable to the following roles:
- Bank professionals in the front, middle and back office engaged in residential mortgage lending (for example, product design, underwriting, administration and management, as well as selling)
- Mortgage brokers who propose, offer, and/or sell residential mortgages
- Managers of employees listed above
- Individuals aspiring to work in any position related to the Hungarian mortgage market

Beyond meeting regulatory requirements, the program is designed to elevate the consultative skills of lending professionals and help them become responsible advisers to their customers, in line with the objectives of Hungarian banks and the evolving expectations of the market.

The program delivers a modern learning experience by using advanced technology to personalize the learning and expedite the impact while minimizing the workload for those who already possess the required skills.

Gergely Fábián, Chief Executive Officer of BIB, noted, “We are delighted to work with Moody’s Analytics and to bring their educational framework and professional knowledge in mortgage lending to Hungary. The program aims to instill best practices in lending for mortgage lenders in the Hungarian Banking industry.”

Béla Öcsi, Chief Executive Officer of the ITCB, added, “The innovative Credit Coach framework from Moody’s Analytics brings an enhanced learning experience for all participants. We are pleased to be able to deliver substantial value to the local banking sector through the collaboration with BIB and Moody’s Analytics.”

“We are honored to collaborate with the BIB and ITCB to deliver a program that represents the highest standards in international credit practices, adapted to the unique context of the Hungarian banking industry,” added Ari Lehavi, Executive Director at Moody’s Analytics. “We look forward to supporting similar institutes across the region in their goal of addressing the certification requirements of the European Mortgage Credit Directive, as applicable in their local market.”

Moody’s Analytics recently collaborated with the Hellenic Banking Institute to offer the Certification of Professional Competence in Mortgage Lending program in Greece.

Click here to learn more about Moody’s Analytics Learning Solutions, including Credit Coach.

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn .

Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.

About the Budapest Institute of Banking

The foundation of the Budapest Institute of Banking (BIB) is rooted in the matching of market needs with the social responsibility objectives of the Magyar Nemzeti Bank (the Central Bank of Hungary) and the Budapest Stock Exchange.

A modern education centre has been created where up-to-date knowledge is transferred in the form of experience-based learning. Forms of edutainment are an integral part of the teaching methodology. Covering the entire operational range of the banking, financial, and insurance sector, the courses grant the opportunity to participants, from experts to top managers, to gain cutting-edge knowledge and to discover professional development opportunities.

The BIB aims to train experts who will be able to address the challenges of the future.

For more information please visit our website: https://www.bib-edu.hu/en .

About International Training Center for Bankers (ITCB)

Founded 30 years ago, ITCB has been providing quality financial education and specialized risk consultancy services for the banking sector in Hungary, Central and Eastern Europe and the Middle East. Building on its long track record and synergies between advisory and training, ITCB’s current offering focuses on tailor-made case study-driven banking seminars, e-learning courses and financial simulations. For more information about ITCB, visit our website .

Contact:

KATERINA SOUMILOVA Moody’s Analytics Communications +1.212.553.1177

Moody's Analytics Media Relations

moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye